Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A317 in Advanced Solid Tumors (China Phase I/II)
CTR20160872Phase 2Completed
- Sponsor
- BeiGene
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Nonhematologic neoplasms, sponsored by BeiGene. Started Dec 2016; status: completed.
02
Drugs
tislelizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20160872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160872.